These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 35530158)

  • 1. Inhibition of the CDK9-cyclin T1 protein-protein interaction as a new approach against triple-negative breast cancer.
    Cheng SS; Qu YQ; Wu J; Yang GJ; Liu H; Wang W; Huang Q; Chen F; Li G; Wong CY; Wong VKW; Ma DL; Leung CH
    Acta Pharm Sin B; 2022 Mar; 12(3):1390-1405. PubMed ID: 35530158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and biological evaluation of novel 4,4'-bipyridine derivatives acting as CDK9-Cyclin T1 protein-protein interaction inhibitors against triple-negative breast cancer.
    Gao G; Li J; Cao Y; Li X; Qian Y; Wang X; Li M; Qiu Y; Wu T; Wang L; Fang M
    Eur J Med Chem; 2023 Dec; 261():115858. PubMed ID: 37837671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a tetrahydroisoquinoline-based CDK9-cyclin T1 protein-protein interaction inhibitor as an anti-proliferative and anti-migration agent against triple-negative breast cancer cells.
    Cheng S; Yang GJ; Wang W; Ma DL; Leung CH
    Genes Dis; 2022 Nov; 9(6):1674-1688. PubMed ID: 36157485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy.
    McLaughlin RP; He J; van der Noord VE; Redel J; Foekens JA; Martens JWM; Smid M; Zhang Y; van de Water B
    Breast Cancer Res; 2019 Jul; 21(1):77. PubMed ID: 31262335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antineoplastic effects of selective CDK9 inhibition with atuveciclib on cancer stem-like cells in triple-negative breast cancer.
    Brisard D; Eckerdt F; Marsh LA; Blyth GT; Jain S; Cristofanilli M; Horiuchi D; Platanias LC
    Oncotarget; 2018 Dec; 9(99):37305-37318. PubMed ID: 30647871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a Potent, selective and orally bioavailable CDK9 degrader for targeting transcription regulation in Triple-Negative breast cancer.
    Nie HJ; Li BF; Sun J; Yuan Y; Zhang ZG; Hu H; Wang WJ; Chen Z; Wang S; Huang W; Diao X; Yu J; Huang R; Chen XH
    Bioorg Chem; 2024 Dec; 153():107876. PubMed ID: 39406109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective inhibition of CDK9 in triple negative breast cancer.
    Mustafa EH; Laven-Law G; Kikhtyak Z; Nguyen V; Ali S; Pace AA; Iggo R; Kebede A; Noll B; Wang S; Winter JM; Dwyer AR; Tilley WD; Hickey TE
    Oncogene; 2024 Jan; 43(3):202-215. PubMed ID: 38001268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-guided design and cloning of peptide inhibitors targeting CDK9/cyclin T1 protein-protein interaction.
    Taghizadeh MS; Taherishirazi M; Niazi A; Afsharifar A; Moghadam A
    Front Pharmacol; 2024; 15():1327820. PubMed ID: 38808256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational study and peptide inhibitors design for the CDK9 - cyclin T1 complex.
    Randjelović J; Erić S; Savić V
    J Mol Model; 2013 Apr; 19(4):1711-25. PubMed ID: 23296566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of Orally Bioavailable and Potent CDK9 Inhibitors for Targeting Transcription Regulation in Triple-Negative Breast Cancer.
    Wang WJ; Gao L; Wang S; Huang W; Meng XY; Hu H; Chen Z; Sun J; Yuan Y; Zhou Y; Diao X; Huang R; Li J; Chen XH
    J Med Chem; 2024 Jun; 67(12):10035-10056. PubMed ID: 38885173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Requirement for a kinase-specific chaperone pathway in the production of a Cdk9/cyclin T1 heterodimer responsible for P-TEFb-mediated tat stimulation of HIV-1 transcription.
    O'Keeffe B; Fong Y; Chen D; Zhou S; Zhou Q
    J Biol Chem; 2000 Jan; 275(1):279-87. PubMed ID: 10617616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast Cancer.
    Wei D; Wang H; Zeng Q; Wang W; Hao B; Feng X; Wang P; Song N; Kan W; Huang G; Zhou X; Tan M; Zhou Y; Huang R; Li J; Chen XH
    J Med Chem; 2021 Oct; 64(19):14822-14847. PubMed ID: 34538051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of HyT-Based Degraders of CDK9-Cyclin T1 Complex.
    Lin R; Yang J; Liu T; Wang M; Ke C; Luo C; Lin J; Li J; Lin H
    Chem Biodivers; 2023 Aug; 20(8):e202300769. PubMed ID: 37349855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The CDK9-cyclin T1 complex mediates saturated fatty acid-induced vascular calcification by inducing expression of the transcription factor CHOP.
    Shiozaki Y; Okamura K; Kohno S; Keenan AL; Williams K; Zhao X; Chick WS; Miyazaki-Anzai S; Miyazaki M
    J Biol Chem; 2018 Nov; 293(44):17008-17020. PubMed ID: 30209133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction between cyclin T1 and SCF(SKP2) targets CDK9 for ubiquitination and degradation by the proteasome.
    Kiernan RE; Emiliani S; Nakayama K; Castro A; Labbé JC; Lorca T; Nakayama Ki K; Benkirane M
    Mol Cell Biol; 2001 Dec; 21(23):7956-70. PubMed ID: 11689688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of Small-Molecule Degraders of the CDK9-Cyclin T1 Complex for Targeting Transcriptional Addiction in Prostate Cancer.
    Li J; Liu T; Song Y; Wang M; Liu L; Zhu H; Li Q; Lin J; Jiang H; Chen K; Zhao K; Wang M; Zhou H; Lin H; Luo C
    J Med Chem; 2022 Aug; 65(16):11034-11057. PubMed ID: 35925880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer.
    Rajput S; Khera N; Guo Z; Hoog J; Li S; Ma CX
    Oncotarget; 2016 Aug; 7(35):56864-56875. PubMed ID: 27486754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recruitment of cyclin-dependent kinase 9 to nuclear compartments during cytomegalovirus late replication: importance of an interaction between viral pUL69 and cyclin T1.
    Feichtinger S; Stamminger T; Müller R; Graf L; Klebl B; Eickhoff J; Marschall M
    J Gen Virol; 2011 Jul; 92(Pt 7):1519-1531. PubMed ID: 21450947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional interaction between cyclin T1/cdk9 and Puralpha determines the level of TNFalpha promoter activation by Tat in glial cells.
    Darbinian N; Sawaya BE; Khalili K; Jaffe N; Wortman B; Giordano A; Amini S
    J Neuroimmunol; 2001 Dec; 121(1-2):3-11. PubMed ID: 11730934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In silico design of small molecule inhibitors of CDK9/cyclin T1 interaction.
    Randjelovic J; Eric S; Savic V
    J Mol Graph Model; 2014 May; 50():100-12. PubMed ID: 24769691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.